JP Morgan Cazenove Maintains Pearson PLC (LON:PSON) As “Neutral”; Has Price Objective Of GBX 740.00; Kornitzer Capital Management Has Boosted Its Ligand Pharmaceuticals (LGND) Holding

December 7, 2017 - By Ellis Scott

They currently have a GBX 740.00 target on Pearson PLC (LON:PSON). JP Morgan Cazenove’s target would suggest a potential upside of 0.30% from the company’s last stock price. This was revealed to investors in analysts note on Thursday morning.

Kornitzer Capital Management Inc increased Ligand Pharmaceuticals (LGND) stake by 83.15% reported in 2017Q2 SEC filing. Kornitzer Capital Management Inc acquired 52,440 shares as Ligand Pharmaceuticals (LGND)’s stock rose 7.66%. The Kornitzer Capital Management Inc holds 115,505 shares with $14.02M value, up from 63,065 last quarter. Ligand Pharmaceuticals now has $2.73B valuation. The stock increased 0.93% or $1.19 during the last trading session, reaching $129.55. About 111,734 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has declined 2.87% since December 7, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.

Pearson plc provides educational materials and learning technologies for teachers and students worldwide. The company has market cap of 5.89 billion GBP. It operates through North America, Growth, and Core divisions. It currently has negative earnings. The firm offers courseware services, including curriculum materials provided in book form and/or via access to digital content; and assessments, such as test development, processing, and scoring services.

The stock increased 2.36% or GBX 17 during the last trading session, reaching GBX 738. About 1.74 million shares traded. Pearson plc (LON:PSON) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 25 analysts covering Pearson PLC (LON:PSON), 7 have Buy rating, 6 Sell and 12 Hold. Therefore 28% are positive. Pearson PLC has GBX 2200 highest and GBX 330 lowest target. GBX 753.87’s average target is 2.15% above currents GBX 738 stock price. Pearson PLC had 329 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Sell” rating given on Monday, May 9 by Liberum Capital. The stock has “Outperform” rating by BNP Paribas on Thursday, August 6. The company was maintained on Friday, July 24 by Deutsche Bank. The firm earned “Neutral” rating on Thursday, December 3 by Nomura. Morgan Stanley maintained the stock with “Overweight” rating in Tuesday, October 4 report. The firm has “Sell” rating given on Friday, February 26 by Liberum Capital. On Monday, September 18 the stock rating was maintained by Liberum Capital with “Sell”. The firm has “Sell” rating by Liberum Capital given on Wednesday, March 8. The stock has “Equal Weight” rating by Barclays Capital on Tuesday, October 18. The rating was maintained by Natixis with “Buy” on Monday, March 21.

Investors sentiment increased to 1.24 in 2017 Q2. Its up 0.06, from 1.18 in 2017Q1. It improved, as 22 investors sold LGND shares while 79 reduced holdings. 36 funds opened positions while 89 raised stakes. 22.57 million shares or 0.91% more from 22.37 million shares in 2017Q1 were reported. Columbia Wanger Asset Management Ltd Liability Co reported 291,037 shares. Hsbc Pcl holds 0.01% or 43,344 shares in its portfolio. Parametrica Ltd, a Hong Kong-based fund reported 1,695 shares. Gabelli Funds Lc invested 0.03% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Blackrock has invested 0.02% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). State Of Alaska Department Of Revenue has invested 0.03% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Castleark Limited Liability Company accumulated 0.31% or 78,680 shares. Intrust Bank Na has invested 0.09% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Capstone Asset Mgmt Co has 2,813 shares. Independent Port Consultants holds 0.06% or 1,177 shares. Gemmer Asset Management Limited Liability Corporation has 53 shares. California-based Meridian Counsel Inc has invested 0.23% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Moreover, Advisory Svcs Ntwk Limited has 0% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 141 shares. Captrust Financial invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). The North Carolina-based Verity Asset Mngmt has invested 0.26% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: